ESC 365 - Cardiovascular risks of PD1 inhibitor therapy in cancer: impact of prior ischemic events on heart failure

Back

ESC Professional Premium Access

Cardiovascular risks of PD1 inhibitor therapy in cancer: impact of prior ischemic events on heart failure - a retrospective cohort study

Session: Miscellaneous clinical studies in heart failure (7)

Topic: Cardiotoxicity of Drugs and Other Therapies

Speaker: Doctor Z. Drobni (Budapest, HU)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Zsofia Dora Drobni

Semmelweis University, Budapest (Hungary)

1 presentation

0 follower

6 more presentations in this session

Who should be prioritized for screening for adult onset dilated cardiomyopathy among first degree relatives?

Speaker: Associate Professor J. Oh (Seoul, KR)

The association between endogenous erythropoietin levels and the risk of heart failure in a Chinese community-based population

Speaker: Doctor H. Xie (Beijing, CN)

AB-HFPEF score: A new and improved HFpEF prediction tool for the Indian patient

Speaker: Doctor A. Jindal (New Delhi, IN)

Longitudinal changes in the prevalence of indicators for the precursor stage B of heart failure: results of the STAAB study

Speaker: Doctor C. Morbach (Wuerzburg, DE)

Gene-echocardiography: unmasking the covert role of fatty acid metabolism gene mutations in adult cardiomyopathy

Speaker: Doctor N. Zhou (Shanghai, CN)

Access the full session

Miscellaneous clinical studies in heart failure (7)

Speakers: Doctor Z. Drobni, Associate Professor J. Oh, Doctor H. Xie, Doctor A. Jindal, Doctor C. Morbach...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources